open access

Vol 6, No 4 (2010)
Other materials agreed with the Editors
Published online: 2010-12-16
Get Citation

Letter to Editor

Piotr Rutkowski
Onkol. Prak. Klin 2010;6(4):216-216.

open access

Vol 6, No 4 (2010)
Miscelleanea
Published online: 2010-12-16

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Letter to Editor

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 4 (2010)

Article type

Other materials agreed with the Editors

Pages

216-216

Published online

2010-12-16

Bibliographic record

Onkol. Prak. Klin 2010;6(4):216-216.

Authors

Piotr Rutkowski

References (5)
  1. Sjöblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 2001; 61(15): 5778–5783.
  2. Kerob D, Pedeutour F, Leboeuf C, et al. Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol. 2008; 26(10): 1757–1759.
  3. Wang J, Morimitsu Y, Okamoto S, et al. COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans. J Mol Diagn. 2000; 2(1): 47–52.
  4. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group, Southwest Oncology Group. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010; 28(10): 1772–1779.
  5. Rutkowski P, Dębiec-Rychter M, Nowecki Zi, et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol. 2011; 25(3): 264–270.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl